Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

05 Mar 2017 - 09 Mar 2017
20 Mar 2017 - 23 Mar 2017
12 Apr 2017 - 14 Apr 2017

Identification of Rare Mutation May Lead to Heart Repair Gene Therapy

By BiotechDaily International staff writers
Posted on 17 Mar 2014
Image: In the heart muscle cell above, the arrows show an early sign of replication (Photo courtesy of Johns Hopkins University).
Image: In the heart muscle cell above, the arrows show an early sign of replication (Photo courtesy of Johns Hopkins University).
ADVERTISEMENT
SARTORIUS AG
Identification of the mutation responsible for an exceedingly rare type of heart defect in infants may pave the way for a gene therapy approach for regenerating adult heart tissue damaged by heart attack or disease.

Investigators at Johns Hopkins University (Baltimore, MD, USA) had been examining the hearts removed from two infant siblings during heart transplant surgery. Initial findings were that cells in the heart muscle (cardiomyocytes) were continuing to divide despite the fact that the infants had passed the age by which such cell division has normally terminated. The investigators established that the infants' genomes contained two abnormal copies of the ALMS1 gene. The same mutation was then found in five infant patients, including two sets of siblings, at the Hospital for Sick Children (Toronto, Canada).

The investigators reported in the March 4, 2014, online edition of the journal Nature Communications that the ALMS1 gene mutation caused a deficiency of the Alström protein that impaired the ability of the heart cells to stop dividing. In a genetically engineered mouse model, animals that lacked the ALMS1 gene displayed increased cardiomyocyte proliferation at two weeks postnatal compared with wild-type littermates. Furthermore, cultured cardiomyocytes divided abnormally after exposure to siRNA (short interfering RNA) that blocked expression of the ALMS1 gene.

“This study offers hope that we can someday find a way to restore the ability of heart cells to divide in response to injury and to help patients recover from many kinds of cardiac dysfunction,” said senior author Dr. Daniel P. Judge, associate professor of cardiology at Johns Hopkins University. “Things usually heal up well in many parts of the body through cell division, except in the heart and the brain. Although other work has generated a lot of excitement about the possibility of treatment with stem cells, our research offers an entirely different direction to pursue in finding ways to repair a damaged heart.”

“The children who helped us recognize the importance of this gene were born with a rare condition that leads to heart failure and many other problems, such as diabetes, obesity, blindness, and deafness,” said Dr. Judge. “Now we hope to apply these discoveries to help millions of others with heart disease.”

Related Links:

Johns Hopkins University
The Hospital for Sick Children
 


Channels

Drug Discovery

view channel
Image: The experimental drug NGI-1 slows cancer growth by blocking glycosylation of the epidermal growth factor receptor (EGFR), which is shown in the above diagram (Photo courtesy of Wikimedia Commons).

Experimental Drug Slows Lung Cancer Growth by Blocking Protein Glycosylation

An interesting new experimental anti-cancer drug slows growth of certain lung tumor cells by preventing the glycosylation of critical cell surface receptor proteins. Asparagine (N)-linked glycosylation... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.